Giant Cell Arteritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Giant Cell Arteritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034


The 7 major giant cell arteritis markets reached a value of US$ 1,130.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,825.2 Million by 2034, exhibiting a growth rate (CAGR) of 4.45% during ​2024-2034​.

The giant cell arteritis market has been comprehensively analyzed in IMARC's new report titled "Giant Cell Arteritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Giant cell arteritis, also known as temporal arteritis, refers to a type of systemic vasculitis that affects medium- to large-sized arteries, most commonly the temporal arteries that run along the sides of the head. The ailment causes inflammation and damage to the walls of the arteries, leading to narrowing or blockage of blood flow. The symptoms can vary widely but generally include severe headaches, scalp tenderness, jaw pain when chewing, fatigue, fever, weight loss, muscle aches, etc. In some cases, the disease can cause permanent vision loss due to damage to the ophthalmic artery, which supplies blood to the optic nerve. The diagnosis of the condition typically involves a combination of clinical evaluation, blood tests, and imaging procedures. A doctor will often start by taking a detailed medical history and performing a physical exam, looking for signs of inflammation, such as tenderness over the temporal arteries. Several blood tests are used to measure markers of inflammation, including erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Additionally, an ultrasound or angiography may be performed to assess the affected arteries and check for signs of blockages.

The rising prevalence of autoimmune disorders, in which the body's immune system targets healthy tissues and causes inflammation in the blood vessels, is primarily driving the giant cell arteritis market. In addition to this, the increasing incidence of several potential risk factors, including respiratory infections, advancing age, inflammatory diseases like polymyalgia rheumatica, etc., is also bolstering the market growth. Furthermore, the widespread adoption of low-dose aspirin in combination with immunosuppressive drugs for reducing the likelihood of blood clot formation and other complications in patients is acting as another significant growth-inducing factor. Besides this, the emerging popularity of biologic therapies, such as tocilizumab, anakinra, abatacept, etc., to target specific components of the immune system involved in the inflammatory process is further creating a positive outlook for the market. Additionally, the escalating utilization of corticosteroid-sparing strategies on account of their several associated benefits, including minimal side effects, enhanced disease control, and a reduced risk of relapse, is also propelling the market growth. Moreover, the introduction of novel image-guided biopsies, such as ultrasound-guided temporal artery biopsy, which has improved the accuracy of diagnosis and lowered the need for invasive surgical biopsy procedures, is expected to drive the giant cell arteritis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the giant cell arteritis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for giant cell arteritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the giant cell arteritis market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the giant cell arteritis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the giant cell arteritis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current giant cell arteritis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the giant cell arteritis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the giant cell arteritis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the giant cell arteritis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of giant cell arteritis across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of giant cell arteritis by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of giant cell arteritis by gender across the seven major markets?
How many patients are diagnosed (​2018-2034​) with giant cell arteritis across the seven major markets?
What is the size of the giant cell arteritis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of giant cell arteritis?
What will be the growth rate of patients across the seven major markets?

Giant Cell Arteritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for giant cell arteritis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the giant cell arteritis market?
What are the key regulatory events related to the giant cell arteritis market?
What is the structure of clinical trial landscape by status related to the giant cell arteritis market?
What is the structure of clinical trial landscape by phase related to the giant cell arteritis market?
What is the structure of clinical trial landscape by route of administration related to the giant cell arteritis market?


1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Giant Cell Arteritis - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (​2018-2023​) and Forecast (​2024-2034​)
4.5 Competitive Intelligence
5 Giant Cell Arteritis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Giant Cell Arteritis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (​2018-2023​)
7.2.2 Epidemiology Forecast (​2024-2034​)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (​2018-2023​)
7.3.2 Epidemiology Forecast (​2024-2034​)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (​2018-2023​)
7.4.2 Epidemiology Forecast (​2024-2034​)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (​2018-2023​)
7.5.2 Epidemiology Forecast (​2024-2034​)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (​2018-2023​)
7.6.2 Epidemiology Forecast (​2024-2034​)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (​2018-2023​)
7.7.2 Epidemiology Forecast (​2024-2034​)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (​2018-2023​)
7.8.2 Epidemiology Forecast (​2024-2034​)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (​2018-2023​)
7.9.2 Epidemiology Forecast (​2024-2034​)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)
8 Giant Cell Arteritis - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Giant Cell Arteritis - Unmet Needs
10 Giant Cell Arteritis - Key Endpoints of Treatment
11 Giant Cell Arteritis - Marketed Products
11.1 List of Giant Cell Arteritis Marketed Drugs Across the Top 7 Markets
11.1.1 Actemra (Tocilizumab) - Chugai Pharmaceutical/Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 Giant Cell Arteritis - Pipeline Drugs
12.1 List of Giant Cell Arteritis Pipeline Drugs Across the Top 7 Markets
12.1.1 KPL 301 - CSL/Kiniksa Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Secukinumab - Novartis
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Guselkumab - Janssen Biotech
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Upadacitinib - AbbVie
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. Giant Cell Arteritis - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Giant Cell Arteritis – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Giant Cell Arteritis - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Giant Cell Arteritis - Market Size
15.2.1.1 Market Size (​2018-2023​)
15.2.1.2 Market Forecast (​2024-2034​)
15.2.2 Giant Cell Arteritis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (​2018-2023​)
15.2.2.2 Market Forecast by Therapies (​2024-2034​)
15.3 Market Scenario - United States
15.3.1 Giant Cell Arteritis - Market Size
15.3.1.1 Market Size (​2018-2023​)
15.3.1.2 Market Forecast (​2024-2034​)
15.3.2 Giant Cell Arteritis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (​2018-2023​)
15.3.2.2 Market Forecast by Therapies (​2024-2034​)
15.3.3 Giant Cell Arteritis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Giant Cell Arteritis - Market Size
15.4.1.1 Market Size (​2018-2023​)
15.4.1.2 Market Forecast (​2024-2034​)
15.4.2 Giant Cell Arteritis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (​2018-2023​)
15.4.2.2 Market Forecast by Therapies (​2024-2034​)
15.4.3 Giant Cell Arteritis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Giant Cell Arteritis - Market Size
15.5.1.1 Market Size (​2018-2023​)
15.5.1.2 Market Forecast (​2024-2034​)
15.5.2 Giant Cell Arteritis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (​2018-2023​)
15.5.2.2 Market Forecast by Therapies (​2024-2034​)
15.5.3 Giant Cell Arteritis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Giant Cell Arteritis - Market Size
15.6.1.1 Market Size (​2018-2023​)
15.6.1.2 Market Forecast (​2024-2034​)
15.6.2 Giant Cell Arteritis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (​2018-2023​)
15.6.2.2 Market Forecast by Therapies (​2024-2034​)
15.6.3 Giant Cell Arteritis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Giant Cell Arteritis - Market Size
15.7.1.1 Market Size (​2018-2023​)
15.7.1.2 Market Forecast (​2024-2034​)
15.7.2 Giant Cell Arteritis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (​2018-2023​)
15.7.2.2 Market Forecast by Therapies (​2024-2034​)
15.7.3 Giant Cell Arteritis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Giant Cell Arteritis - Market Size
15.8.1.1 Market Size (​2018-2023​)
15.8.1.2 Market Forecast (​2024-2034​)
15.8.2 Giant Cell Arteritis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (​2018-2023​)
15.8.2.2 Market Forecast by Therapies (​2024-2034​)
15.8.3 Giant Cell Arteritis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Giant Cell Arteritis - Market Size
15.9.1.1 Market Size (​2018-2023​)
15.9.1.2 Market Forecast (​2024-2034​)
15.9.2 Giant Cell Arteritis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (​2018-2023​)
15.9.2.2 Market Forecast by Therapies (​2024-2034​)
15.9.3 Giant Cell Arteritis - Access and Reimbursement Overview
16 Giant Cell Arteritis - Recent Events and Inputs From Key Opinion Leaders
17 Giant Cell Arteritis Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Giant Cell Arteritis Market – Strategic Recommendations
19 Appendix

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings